CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Eli Lilly's biggest catalyst at the moment comes from its hit weight loss medications, Mounjaro and Zepbound. Lilly is investing billions of dollars to scale manufacturing efforts as demand for ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs. The company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs ...

Pharmaceutical giant Eli Lilly's (LLY) GLP-1 weight-loss drug Zepbound received approval by the US Food and Drug Administration (FDA) to treat sleep apnea. Rumble (RUM) shares skyrocket by over 80 ...